Info

ISM Therapeutics is developing a radioprotective drug based on our ISM technology under a government contract for the DOD. ISM Therapeutics has discovered and developed an ISM-based therapeutic for cystic fibrosis: INO-4995 was discovered and developed to treat cystic fibrosis and human clinical trials are targeted to begin in 2007. The cost of developing the CF drug through phase I trials is approximately $12M and will take approximately 2 years. In addition, ISM Therapeutics has several compounds in its portfolio with anti-inflammatory activity. Key AssetsActive compound collection: ISM Therapeutics has identified, synthesized and tested distinct, patented active compound series that have yielded a number of drug candidates with potential therapeutic applications. Scientific expertise.Our founder and Chief Scientific Officer, Dr. Alexis Traynor-Kaplan, has over 25 years expertise in the area and identified one of the first ISMs. ISM Therapeutics has a world-renowned SAB with expertise in ISM technologies and chemistry. Control of critical patents. ISM Therapeutics co-owns and has an exclusive worldwide license from the University of California, San Diego for 3 issued patents covering key composition of matter and method of use claims. ISM Therapeutics also maintains an extensive portfolio of domestic and international filings on inventions derived from internal research. Company Funding to date:Approximately $5M in non-dilutive investments: 2000-2006: $1.9M in Cystic Fibrosis Foundation grants to discover and develop a CF drug, INO-4995 1998-2006: $2M in NIH SBIR grants to initiate pipeline programs in CF, cancer and inflammation 10/2006- 10/2007: $1.1M DOD non-dilutive government appropriation to develop ISMs as radioprotectants $2.5M in an investment series A round (2004) (primarily angels, founders and partners) For more information, please contact: